Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.23.45 - memapsin 1

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Alzheimer Disease
1,3-Oxazines as BACE1 and/or BACE2 inhibitors: a patent evaluation (WO2012156284).
A new aspartyl protease on 21q22.3, BACE2, is highly similar to Alzheimer's amyloid precursor protein beta-secretase.
A system for enhancing genome-wide coexpression dynamics study.
Altered beta-secretase enzyme kinetics and levels of both BACE1 and BACE2 in the Alzheimer's disease brain.
BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.
BACE1 and BACE2 enzymatic activities in Alzheimer's disease.
BACE2 degradation is mediated by both the proteasome and lysosome pathways.
BACE2 degradation mediated by the macroautophagy-lysosome pathway.
BACE2 distribution in major brain cell types and identification of novel substrates.
BACE2 is stored in secretory granules of mouse and rat pancreatic beta cells.
BACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein.
BACE2, a conditional ?-secretase, contributes to Alzheimer's disease pathogenesis.
BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome.
Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein.
Characterization of a mouse model overexpressing beta-site APP-cleaving enzyme 2 reveals a new role for BACE2.
Chromosome 21 BACE2 haplotype associates with Alzheimer's disease: a two-stage study.
Common BACE2 Polymorphisms are Associated with Altered Risk for Alzheimer's Disease and CSF Amyloid Biomarkers in APOE ?4 Non-Carriers.
Coordinated expression of beta-amyloid precursor protein and the putative beta-secretase BACE and alpha-secretase ADAM10 in mouse and human brain.
Crystal structure of human BACE2 in complex with a hydroxyethylamine transition-state inhibitor.
Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, ?-site amyloid precursor protein cleaving enzyme 1 (BACE1) Inhibitor Lacking Hypopigmentation.
Enzymic properties of recombinant BACE2.
Glycosaminoglycan-induced activation of the beta-secretase (BACE1) of Alzheimer's disease.
Identification of Human Islet Amyloid Polypeptide as a BACE2 Substrate.
Inhibition of BACE2 counteracts hIAPP-induced insulin secretory defects in pancreatic ?-cells.
Insights from modeling the tertiary structure of human BACE2.
Lack of association between the polymorphisms of beta-site APP-cleaving enzyme 2 (BACE2) 5'-flanking region and sporadic Alzheimer's disease.
Large scale refolding and purification of the catalytic domain of human BACE-2 produced in E. coli.
Mapping the conformational space accessible to BACE2 using surface mutants and cocrystals with Fab fragments, Fynomers and Xaperones.
Mutations in the open reading frame of the beta-site APP cleaving enzyme (BACE) locus are not a common cause of Alzheimer's disease.
Natural antisense transcripts of Alzheimer's disease associated genes.
Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice.
Reversible and Species-Specific Depigmentation Effects of AZD3293, a BACE Inhibitor for the Treatment of Alzheimer's Disease, Are Related to BACE2 Inhibition and Confined to Epidermis and Hair.
Salidroside attenuates hypoxia-induced abnormal processing of amyloid precursor protein by decreasing BACE1 expression in SH-SY5Y cells.
Specific BACE1 genotypes provide additional risk for late-onset Alzheimer disease in APOE epsilon 4 carriers.
Specificity of memapsin 1 and its implications on the design of memapsin 2 (beta-secretase) inhibitor selectivity.
The association of beta-site APP cleaving enzyme (BACE) C786G polymorphism with Alzheimer's disease.
The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain.
Asthma
Genes Involved in Interleukin-1 Receptor Type II Activities Are Associated With Asthmatic Phenotypes.
Carcinogenesis
Cell surface GRP78 regulates BACE2 via lysosome-dependent manner to maintain mesenchymal phenotype of glioma stem cells.
m6A RNA hypermethylation-induced BACE2 boosts intracellular calcium release and accelerates tumorigenesis of ocular melanoma.
TGF?1-induced beta-site APP-cleaving enzyme 2 upregulation promotes tumorigenesis through the NF-?B signalling pathway in human gliomas.
Dementia
Crystal structure of human BACE2 in complex with a hydroxyethylamine transition-state inhibitor.
Down syndrome, Alzheimer's disease and seizures.
Erratum to "Polymorphisms in BACE2 may affect the age of onset Alzheimer's dementia in Down syndrome" [Neurobiol. Aging 35 (2014) 1513.e1-1513.e5].
Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain.
Polymorphisms in BACE2 may affect the age of onset Alzheimer's dementia in Down syndrome.
Diabetes Mellitus, Type 2
Automated assessment of ?-cell area and density per islet and patient using TMEM27 and BACE2 immunofluorescence staining in human pancreatic ?-cells.
BACE2 plays a role in the insulin receptor trafficking in pancreatic beta-cells.
BACE2 suppression promotes ?-cell survival and function in a model of type 2 diabetes induced by human islet amyloid polypeptide overexpression.
Design of Potent and Highly Selective Inhibitors for Human ?-Secretase 2 (Memapsin 1), a Target for Type 2 Diabetes.
Diabetes, Gestational
Replication of previous genome-wide association studies of HKDC1, BACE2, SLC16A11 and TMEM163 SNPs in a gestational diabetes mellitus case-control sample from Han Chinese population.
Down Syndrome
A new aspartyl protease on 21q22.3, BACE2, is highly similar to Alzheimer's amyloid precursor protein beta-secretase.
BACE-2 is overexpressed in Down's syndrome.
BACE2 expression increases in human neurodegenerative disease.
BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome.
Characterization of a mouse model overexpressing beta-site APP-cleaving enzyme 2 reveals a new role for BACE2.
Correction: Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain.
Crystal structure of human BACE2 in complex with a hydroxyethylamine transition-state inhibitor.
Elevated expression of beta-site amyloid precursor protein cleaving enzyme 2 in brains of patients with Down syndrome.
In vivo effects of APP are not exacerbated by BACE2 co-overexpression: behavioural characterization of a double transgenic mouse model.
Insights from modeling the tertiary structure of human BACE2.
Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain.
Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice.
Polymorphisms in BACE2 may affect the age of onset Alzheimer's dementia in Down syndrome.
Protein expression of BACE1, BACE2 and APP in Down syndrome brains.
Frontotemporal Dementia
BACE2 expression increases in human neurodegenerative disease.
Glioblastoma
TGF?1-induced beta-site APP-cleaving enzyme 2 upregulation promotes tumorigenesis through the NF-?B signalling pathway in human gliomas.
Glioma
Cell surface GRP78 regulates BACE2 via lysosome-dependent manner to maintain mesenchymal phenotype of glioma stem cells.
TGF?1-induced beta-site APP-cleaving enzyme 2 upregulation promotes tumorigenesis through the NF-?B signalling pathway in human gliomas.
Hirschsprung Disease
Association Analysis of Variants of DSCAM and BACE2 With Hirschsprung Disease Susceptibility in Han Chinese and Functional Evaluation in Zebrafish.
Identification of Genes Associated with Hirschsprung Disease, Based on Whole-genome Sequence Analysis, and Potential Effects on Enteric Nervous System Development.
Hyperinsulinism
BACE2 suppression in mice aggravates the adverse metabolic consequences of an obesogenic diet.
Hypopigmentation
Reversible and Species-Specific Depigmentation Effects of AZD3293, a BACE Inhibitor for the Treatment of Alzheimer's Disease, Are Related to BACE2 Inhibition and Confined to Epidermis and Hair.
Insulin Resistance
BACE2 suppression in mice aggravates the adverse metabolic consequences of an obesogenic diet.
Lymphoma, B-Cell
Exposure of isoflurane-treated cells to hyperoxia decreases cell viability and activates the mitochondrial apoptotic pathway.
Melanoma
m6A RNA hypermethylation-induced BACE2 boosts intracellular calcium release and accelerates tumorigenesis of ocular melanoma.
memapsin 1 deficiency
BACE2 suppression promotes ?-cell survival and function in a model of type 2 diabetes induced by human islet amyloid polypeptide overexpression.
Muscular Diseases
BACE2 is stored in secretory granules of mouse and rat pancreatic beta cells.
Myositis
BACE2 is stored in secretory granules of mouse and rat pancreatic beta cells.
Presence of BACE1 and BACE2 in muscle fibres of patients with sporadic inclusion-body myositis.
Neoplasms
Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile.
Crystal structure of human BACE2 in complex with a hydroxyethylamine transition-state inhibitor.
m6A RNA hypermethylation-induced BACE2 boosts intracellular calcium release and accelerates tumorigenesis of ocular melanoma.
TGF?1-induced beta-site APP-cleaving enzyme 2 upregulation promotes tumorigenesis through the NF-?B signalling pathway in human gliomas.
The emerging role of ?-secretases in cancer.
Neuroblastoma
Morphine via nitric oxide modulates beta-amyloid metabolism: a novel protective mechanism for Alzheimer's disease.
Neurodegenerative Diseases
BACE2 expression increases in human neurodegenerative disease.
Neuroinflammatory Diseases
The modulatory role of prime identified compounds in Geophila repens in mitigating scopolamine-induced neurotoxicity in experimental rats of Alzheimer's disease via attenuation of cholinesterase, ?-secretase, MAPt levels and inhibition of oxidative stress imparts inflammation.
Obesity
BACE2 suppression in mice aggravates the adverse metabolic consequences of an obesogenic diet.
Osteosarcoma
Prognostic scoring system for osteosarcoma using network-regularized high-dimensional Cox-regression analysis and potential therapeutic targets.
Pancreatitis
Loss of Bace1 in mice does not alter the severity of caerulein induced pancreatitis.
Parkinson Disease
Cerebrospinal fluid A?42 levels and APP processing pathway genes in Parkinson's disease.
Pre-Eclampsia
Protein misfolding, congophilia, oligomerization, and defective amyloid processing in preeclampsia.
Prostatic Neoplasms
[Effects of long non-coding RNA RP1-90L14.1 on the biological behaviors of cancer prostate LNCaP cells and its regulating mechanisms].